- 53.2k views
Beyond Breathless: Innovative Approaches to PAH Management
Pulmonary arterial hypertension (PAH) is a progressive and debilitating disease that affects the arteries in the lungs, leading to increased pulmonary arterial pressure and right heart failure. Despite significant advances in the management of PAH in recent years, it remains a challenging disease to treat, and many patients continue to experience significant symptoms and reduced quality of life. However, there are several innovative approaches to PAH management that are currently being explored and show promise in improving outcomes for patients. One such approach is the use of combination therapy. While single-agent therapy has traditionally been the first-line treatment for PAH, recent studies have shown that combining different classes of drugs can lead to better outcomes. For example, combining an endothelin receptor antagonist with a phosphodiesterase type 5 inhibitor has been shown to improve exercise capacity and reduce clinical worsening in patients with PAH. Another promising approach is the use of novel drugs that target specific pathways involved in the development of PAH. For example, selexipag, a prostacyclin receptor agonist, has been shown to improve exercise capacity and reduce hospitalization rates in patients with PAH. Similarly, macitentan, a dual endothelin receptor antagonist, has been shown to improve exercise capacity and reduce clinical worsening in patients with PAH.
About the Speaker
Dr. Bhagwan Mantri
Consultant Pulmonologist and Critical care specialist
Upcoming Case Discussions
H. pylori Treatment with PYELRA®: Best Practices
PYLERA® is a medication used for the treatment of Helicobacter pylori (H. pylori) infection, a common cause of stomach ulcers and gastritis. It contains a combination of three active ingredients: bismuth subcitrate potassium, metronidazole, and tetracycline. This combination works synergistically to eradicate H. pylori bacteria and reduce associated symptoms. Treatment with PYLERA® typically involves taking multiple capsules four times a day for a specified duration, as prescribed by a healthcare provider. It is important to follow the treatment regimen as directed and to discuss potential side effects
Amenorrhea: Clinical Features & Treatment
Amenorrhea refers to the absence of menstrual periods in women of reproductive age and can be classified as either primary or secondary. Clinical features of amenorrhea may include hot flashes, vaginal dryness, breast changes, headaches, and hair loss, depending on the underlying cause such as hormonal imbalances, stress, or anatomical abnormalities. Diagnosis involves a thorough medical history, physical examination, and tests including hormone levels (e.g., FSH, LH, estradiol, thyroid function tests) and imaging studies (e.g., ultrasound, MRI). Treatment depends on the cause and may include lifestyle modifications, hormone replacement therapy, medications to induce ovulation, or surgical intervention in cases of structural abnormalities. Management aims to address underlying factors, restore menstrual function, and address any associated symptoms or complications of amenorrhea. Regular follow-up and monitoring are essential to assess treatment efficacy and address any new concerns or changes in symptoms.
Case Scenario: Role of Point Care Ultrasound in NICU
Point-of-care ultrasound in the NICU allows for early diagnosis of various conditions such as respiratory distress, intraventricular hemorrhage, and congenital heart defects, aiding in timely interventions. POCUS enables real-time bedside monitoring of neonatal patients, providing immediate feedback on cardiac function, lung status, and fluid balance without the need for transportation to a separate imaging facility. Unlike traditional imaging modalities such as X-rays and CT scans, POCUS uses ultrasound waves that do not involve ionizing radiation, making it safer for frequent use in critically ill neonates. POCUS helps assess hemodynamics, including cardiac output, systemic and pulmonary blood flow, and evaluation of ductus arteriosus patency, guiding treatment decisions in hemodynamically unstable infants. Lung ultrasound provides rapid assessment of lung aeration and helps differentiate between different lung pathologies, aiding in the management of respiratory distress syndrome and other respiratory conditions. POCUS devices are portable and easy to use at the bedside, allowing neonatologists and intensivists to obtain immediate diagnostic information during rounds or emergent situations.
Oral Cancer Awareness: Strategies for Prevention
Promoting oral cancer awareness through educational campaigns aimed at informing the public about risk factors, signs, and symptoms of oral cancer is crucial for early detection and prevention. Encouraging individuals to quit smoking and avoid excessive alcohol consumption significantly reduces the risk of developing oral cancer, as these are major contributing factors. Emphasizing a balanced diet rich in fruits and vegetables, which are high in antioxidants, can help reduce the risk of oral cancer and support overall oral health. Routine dental visits for oral examinations and screenings play a vital role in detecting precancerous lesions or early-stage oral cancers, enabling prompt intervention and treatment. Encouraging vaccination against human papillomavirus (HPV), a known risk factor for oral cancer, especially among adolescents and young adults, can reduce the risk of developing HPV-related oral cancers. Teaching individuals how to perform self-examinations of their oral cavity to identify any changes or abnormalities, such as persistent sores or lumps, encourages early detection and timely medical evaluation.
Osteoporosis: Basic Facts
Postpartum hemorrhage (PPH) is a significant complication following childbirth, characterized by excessive bleeding within 24 hours of delivery. It's a leading cause of maternal mortality globally. PPH can occur due to various factors, including uterine atony (failure of the uterus to contract), trauma during childbirth, retained placental tissue, or coagulation disorders. Prompt recognition and intervention are crucial to prevent severe consequences. Management typically involve uterine massage, administration of uterotonic medications, uterine artery embolization, or, in severe cases, surgical interventions like hysterectomy. Timely and effective management strategies are essential to reduce maternal morbidity and mortality associated with PPH. Osteoporosis is a progressive bone disease characterized by decreased bone density and structural deterioration, leading to an increased risk of fractures, particularly in the spine, hips, and wrists. It often develops silently over years, with no symptoms until a fracture occurs. Factors such as aging, hormonal changes, inadequate nutrition (especially calcium and vitamin D deficiency), sedentary lifestyle, and certain medications contribute to its development. Prevention and management strategies include weight-bearing exercises, adequate calcium and vitamin D intake, lifestyle modifications to reduce risk factors, and sometimes medication to strengthen bones and reduce fracture risk. Early detection through bone density testing and proactive intervention are crucial in mitigating its impact on individuals' health and quality of life.
Author Post
Impact
+
Talks
+
webinar
+
no.of registrations
One liner about speaker
Why is speaker relevant?
Dr. Bhagwan Mantri's Talks on Assimilate
- 18th-May-2023, TIME : 6:00PM - 7:00PM
- 0
Pulmonary arterial hypertension (PAH) is a progressive and debilitating disease that affects the arteries in the lungs, leading to increased pulmonary arterial pressure and right heart failure. Despite significant advances in the management of PAH in recent years, it remains a challenging disease to treat, and many patients continue to experience significant symptoms and reduced quality of life. However, there are several innovative approaches to PAH management that are currently being explored and show promise in improving outcomes for patients. One such approach is the use of combination therapy. While single-agent therapy has traditionally been the first-line treatment for PAH, recent studies have shown that combining different classes of drugs can lead to better outcomes. For example, combining an endothelin receptor antagonist with a phosphodiesterase type 5 inhibitor has been shown to improve exercise capacity and reduce clinical worsening in patients with PAH. Another promising approach is the use of novel drugs that target specific pathways involved in the development of PAH. For example, selexipag, a prostacyclin receptor agonist, has been shown to improve exercise capacity and reduce hospitalization rates in patients with PAH. Similarly, macitentan, a dual endothelin receptor antagonist, has been shown to improve exercise capacity and reduce clinical worsening in patients with PAH.
- 18th-May-2023, TIME : 6:00PM - 7:00PM
- 0
Pulmonary arterial hypertension (PAH) is a progressive and debilitating disease that affects the arteries in the lungs, leading to increased pulmonary arterial pressure and right heart failure. Despite significant advances in the management of PAH in recent years, it remains a challenging disease to treat, and many patients continue to experience significant symptoms and reduced quality of life. However, there are several innovative approaches to PAH management that are currently being explored and show promise in improving outcomes for patients. One such approach is the use of combination therapy. While single-agent therapy has traditionally been the first-line treatment for PAH, recent studies have shown that combining different classes of drugs can lead to better outcomes. For example, combining an endothelin receptor antagonist with a phosphodiesterase type 5 inhibitor has been shown to improve exercise capacity and reduce clinical worsening in patients with PAH. Another promising approach is the use of novel drugs that target specific pathways involved in the development of PAH. For example, selexipag, a prostacyclin receptor agonist, has been shown to improve exercise capacity and reduce hospitalization rates in patients with PAH. Similarly, macitentan, a dual endothelin receptor antagonist, has been shown to improve exercise capacity and reduce clinical worsening in patients with PAH.